What policy makers need to know about COVID-19 protective immunity

Studdert, 2020, Disease control, civil liberties, and mass testing—calibrating restrictions during the COVID-19 pandemic, N Engl J Med, 10.1056/NEJMp2007637

Martinez, 2020, Compounds with therapeutic potential against novel respiratory 2019 coronavirus, Antimicrob Agents Chemother, 64, e00399, 10.1128/AAC.00399-20

Amanat, 2020, SARS-CoV-2 vaccines: status report, Immunity, 52, 583, 10.1016/j.immuni.2020.03.007

Thanh Le, 2020, The COVID-19 vaccine development landscape, Nat Rev Drug Discov, 10.1038/d41573-020-00073-5

Adams, 2020, Evaluation of antibody testing for SARS-Cov-2 using ELISA and lateral flow immunoassays, bioRxiv

Plotkin, 1999, Vaccination against the major infectious diseases, CR Acad Sci III, 322, 943, 10.1016/S0764-4469(00)87191-7

Plotkin, 2001, Immunologic correlates of protection induced by vaccination, Pediatr Infect Dis J, 20, 63, 10.1097/00006454-200101000-00013

Tan, 2020, Viral kinetics and antibody responses in patients with COVID-19, medRxiv

Stanley, 2014, Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge, Nat Med, 20, 1126, 10.1038/nm.3702

Li, 2008, T cell responses to whole SARS coronavirus in humans, J Immunol, 181, 5490, 10.4049/jimmunol.181.8.5490

Temperton, 2005, Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes, Emerg Infect Dis, 11, 411, 10.3201/eid1103.040906

Choe, 2017, MERS-CoV antibody responses 1 year after symptom onset, South Korea, 2015, Emerg Infect Dis, 23, 1079, 10.3201/eid2307.170310

Channappanavar, 2014, T cell-mediated immune response to respiratory coronaviruses, Immunol Res, 59, 118, 10.1007/s12026-014-8534-z

Anderson, 1985, Vaccination and herd immunity to infectious diseases, Nature, 318, 323, 10.1038/318323a0

Li, 2020, Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia, N Engl J Med, 382, 1199, 10.1056/NEJMoa2001316

Guerra, 2017, The basic reproduction number (RO) of measles: a systematic review, Lancet Infect Dis, 17, e420, 10.1016/S1473-3099(17)30307-9

Wu, 2020, Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications, bioRxiv

Feldmann, 2020, Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed, Lancet, 10.1016/S0140-6736(20)30858-8